Including People with Kidney Diseases in COVID-19 Clinical Trials

In addition to threatening the lives of people with kidney diseases with risk of severe disease and infection, the COVID-19 pandemic put in jeopardy the advancement of innovative therapies for people with kidney diseases that have emerged over the past decade. In the early days of the pandemic, the Board of Directors acted quickly to identify the most acute needs faced by member organizations and the broader community. Including people with kidney diseases in clinical trials for COVID-19 vaccines and therapies was identified as a high priority need resulting in two statements from the Board and continuing follow up work with clinical trial sponsors.

Making the Case for Change: Including People with Kidney Diseases in COVID-19 Trials, May 14, 2020

Including People with Kidney Diseases in COVID-19 Trials: Opportunity for Participation in Vaccine Trials, September 14, 2020